Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine and Capecitabine in Stage IV Breast Cancer
NCT00194727Phase 2Completed
- Sponsor
- University of Washington
- Start
- May 2002
- Primary completion
- Mar 2011
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and capecitabine in breast cancer, sponsored by University of Washington. Primary endpoint: Best Response. Started May 2002; status: completed.
02
Drugs
vinorelbinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00194727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00194727.